Brief: Everest Medicines Announces Approval Of Xerava In China
16/03/2023 12:40
March 16 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ANNOUNCES APPROVAL OF XERAVA IN CHINA
FOR THE
TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULT
PATIENTS
* EVEREST MEDICINES LTD - PLANS TO COMMERCIALLY LAUNCH
XERAVA IN
CHINA IN Q3, 2023
Source text for Eikon: ID:nPnb8xjmya
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region